OncoLize
About
About
OncoLize (2017) is based in Maastricht, The Netherlands.
We develop high performance oncology products for localized and slow delivery of drugs, making our products:
- Much better at eradicating the tumor
- …with far less side-effects
- … and triple A: Accessible and Affordable for All
Our injectable drug depots are simple to use, effective, safe and affordable.
We are currently preparing advanced formulations for First-in-Human trials using a selection of well-known Chemo-drugs. This is based on preliminary PDX-mice studies with human Lung- and Pancreatic tumor grafts. These aggressive tumors were halted in their growth and reversed towards eradication of the tumor mass… even without the support of an intact immune system, which human patients normally do have!
Standard-of-care, generic Chemo was combined with the novelOCL-platformand injected intra-tumor but at much lower quantities than systemic dosing would dictate. No adverse reactions, neither locally or systemically were found.
What we have accomplished in other applications with our local drug delivery depots:
- the level of the druginside the target tissue is 10 to 100x higherthan ever could be achieved through pills, transdermal patches or injections into blood veins;
- the level of drugoutside the target tissue is up to 1000x lowerthan inside the target tissue, often not measurable anymore within a day, while locally present for weeks on end if we so choose to;
- The requiredtotal drug-load was up to 300x lessthan via the other routes of administration.
We have recently upgraded our injectable depot platform to the novelOCL-technology, which is i) faster to formulate and with a broader range of different types of drugs, ii) easier to use and to scale-up; iii) faster to obtain approvals with; and iv) less expensive towards advanced clinical trial development… compared to our previous platform InGell.
Surgeons and oncologists can inject these products straight into the tumor using standard-of-care guided catheters or long, thin needles.
Over time, the depot slowly dissolves, releasing the drug inside the tumor and keeping it there in sufficiently high concentrations… where it should be!
Our Team
Meet Our Team
CEO
The company was founded by Mike de Leeuw (CEO), who previously founded InGell Labs (2010), Branching Tree (2008) and DSM BioMedical (2005) and has a track record in re-structuring and re-financing other start-up’s within the controlled release/ biomedical materials space for drug delivery and cell therapy.
CTO
Mike is joined by dr.Leo de Leede (CTO), a long-time biopharmaceutical expert using polymer-enabled drug delivery in a.o. Organon/MSD – Yamanuchi/Astellas – OctoPlus/Dr.Reddy – Branching Tree/ InGell Labs.
CSO
As of April 2023 they are joined by Helena Kelly (CSO), full time professor at RCSI and the inventor of the licensed OncoLize Technology platform.
We switched to the OCL-platform, which is faster to formulate, easier to use in the clinic and far less costly to scale-up and approve (compared to our previous platform).
We have dedicated ourselves to develop products that deal with the urgent unmet needs for the ‘rare and deadly tumor diseases’.
Why?
- Because we have seen too much suffering within our families, friends and colleagues.
- Because little progress has been made for aggressive Pancreatic-, Lung-, Liver-, Brain-tumors and various other less frequent occurring solid tumors.
- Because most new developments for these diseases come out very expensive, marginally effective if at all, and certainly not accessible for all.
We believe that everybody should have access to the best possible care for these aggressive tumor diseases.
We are certain that this can be done by localizing generic drugs and novel drugs alike, with much better effect, far less side-effects, and at much lower costs to the national healthcare systems.
